Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: Impact of glucagon on fibrinolysis

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 4, 2007, Pages 327-334

  Henkel, Elena ^a   Gallo, Sarsta ^a   Siegert, Gilvina ^a   Koehler, Cabriele ^a   Hanefeld, Markolf ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Glucagon; Impaired glucose tolerance; Insulin resistance; Plasminogen activator inhibitor; Type 2 diabetes

Indexed keywords

GLUCAGON; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FIBRINOLYSIS; GLUCAGON BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INDEPENDENT VARIABLE; INSULIN RESISTANCE; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; SCREENING TEST; UNIVARIATE ANALYSIS;

AGED; AREA UNDER CURVE; DIABETES MELLITUS, TYPE 2; FIBRINOLYSIS; GLUCAGON; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34247859147     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32809cc90b     Document Type: Article

References (30)

1. Olexa P, Olexova M. Plasminogen activator inhibitor-1 (PAI-1), ischemic heart disease and diabetes mellitus. Vnitr Lek 2003; 49:222-226.
2. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43:104-109.
3. Leurs PB, Stolk RP, Hamulyak K, Van Oerle R, Grobbee DE, Wolffenbuttel BH. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 2002; 25:1340-1345.
4. Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. Metabolism 2005; 54:1168-1173.
5. Okopien B, Stachura-Kulach A, Kulach A, Kowalski J, Zielinski M, Wisniewska-Wanat M, et al. The risk of atherosclerosis in patients with impaired glucose tolerance. Res Commun Mol Pathol Pharmacol 2003; 113-114:87-95.
6. Sobel BE. Insulin resistance and thrombosis: a cardiologist's view. Am J Cardiol 1999; 84:37J-41J.
7. Bastard JP, Pieroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 2000; 16:192-201.
8. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283:221-228.
9. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 1994; 89:321-330.
10. Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 9:764-770.
11. Pandolfi A, Giaccari A, Cilli C, Alberta MM, Morviducci L, De Filippis EA, et al. Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat. Acta Diabetol 2001; 38:71-76.
12. Henkel E, Temelkova-Kurktschiev T, Koehler C, Pietzsch J, Leonhardt W, Hanefeld M. Impaired glucose tolerance is not associated with lipid intolerance. Diabetes Nutr Metab 2002; 15:84-90.
13. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-1197.
14. Alberti KG, Zimmet PZ. Definition, diagnosis and cassification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
15. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989; 79:101-106.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
17. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000; 31:26-32.
18. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 1993; 36:817-825.
19. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004; 91:861-872.
20. Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes. Diabet Med 2000; 17:835-840.
21. Weber P, Schrezenmeir J, Fenselau S, Ausieker S, Probst R, Zuchhold D, et al. Prolonged postprandial increment in triglycerides and decreased postprandial response of very low density lipoproteins in type 2 diabetics following an oral lipid load. Dietary lipids and insulin action. Ann N Y Acad Sci 1993; 683:315-321.
22. Pannacciulli N, De Mitrio V, Marino R, Giorgino R, De Pergola G. Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects. Obes Res 2002; 10:717-725.
23. Henkel E, Kohler C, Temelkova-Kurktschiev T, Hanefeld M. Predictors of abnormal glucose tolerance in persons at risk of type 2 diabetes: the RIAD study. Dtsch Med Wochenschr 2002; 127:953-957.
24. Eliasson MC, Jansson JH, Lindahl B, Stegmayr B. High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study. Cardiovasc Diabetol 2003; 2:19.
25. Oakley FR, Sanders TA, Miller GJ. Postprandial effects of an oleic acid-rich oil compared with butter on clotting factor VII and fibrinolysis in healthy men. Am J Clin Nutr 1998; 68:1202-1207.
26. Sanders TA, Oakley FR, Cooper JA, Miller GJ. Influence of a stearic acid-rich structured triacylglycerol on postprandial lipemia, factor VII concentrations, and fibrinolytic activity in healthy subjects. Am J Clin Nutr 2001; 73:715-721.
27. Byrne CD, Wareham NJ, Martensz ND, Humphries SE, Metcalfe JC, Grainger DJ. Increased PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-beta levels. Atherosclerosis 1998; 140:45-53.
28. Saigo M, Abe S, Ogawa M, Yamashita T, Biro S, Minagoe S, et al. Imbalance of plasminogen activator inhibitor-I/tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction. Thromb Haemost 2001; 86:1197-1203.
29. Seki T, Miyasu T, Noguchi T, Hamasaki A, Sasaki R, Ozawa Y, et al. Reciprocal regulation of tissue-type and urokinase-type plasminogen activators in the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation of fibrinolytic factors in the mature adipocytes. J Cell Physiol 2001; 189:72-78.
30. Toft I, Bonaa KH, Ingebretsen OC, Nordoy A, Birkeland KI, Jenssen T. Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension. Arterioscler Thromb Vasc Biol 1997; 17:553-55